<DOC>
	<DOCNO>NCT01857024</DOCNO>
	<brief_summary>The primary objective study ass post-approval clinical setting safety profile sevelamer carbonate ( Renvela® ) tablets powder adult hyperphosphataemic chronic kidney disease ( CKD ) patient dialysis serum phosphorus ≥1.78 mmol/L . Patients treat accordance Renvela® Summary Product Characteristics ( SmPC ) follow accord investigator 's standard clinical practice management . Each patient follow 12 month time start dialysis , whichever occur first .</brief_summary>
	<brief_title>Post Authorisation Safety Study Renvela® Chronic Kidney Disease Patients Not Dialysis With Hyperphosphataemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Adult Chronic Kidney Disease ( CKD ) patient dialysis serum phosphorus ≥ 1.78 mmol/L . Prescribed Renvela ( 800 mg tablet 2.4 g powder oral suspension ) accordance Renvela SmPC . Provide sign informed consent ( patient legally authorised representative )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>